Full Press Release Details
Technologies to Ring Nasdaq Closing Bell Today
ANTONIO, Texas (April 5, 2023) - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the
need for noninvasive, accurate tests for the detection of early-stage cancer, will ring the Nasdaq Stock Market closing bell this afternoon
to commemorate the Company's 2022 initial public offering (IPO).
you to Nasdaq for giving us the opportunity to participate in one of Wall Street's most time-honored traditions," bioAffinity
Technologies President and CEO Maria Zannes said. "When we ring the bell this afternoon, we will be celebrating the many milestones
and scientific discoveries that led to the development of our first commercial product, CyPath Lung, which can detect
lung cancer at the earliest stages when treatment options are more effective and lead to longer, healthier lives."
Nasdaq Stock Market closing bell ceremony will run from approximately 3:45 to 4:05 p.m. Eastern time. A live stream of the event will
be available at https://livestream.com/accounts/27896496/events/10809033 and on the Nasdaq Facebook and Twitter pages.
(Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Its diverse offering of data, analytics,
software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company,
technology solutions and career opportunities, visit Nasdaq on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
bioAffinity Technologies, Inc.
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment.
The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity and specificity
for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology
Services. OncoSelect Therapeutics , LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown
in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company's platform technologies are
conducted in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com and follow
us on LinkedIn and Twitter.
press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company's
offering of common shares. Forward-looking statements can be identified by words such as "believes," "expects,"
"estimates," "intends," "may," "plans," "will" and similar expressions, or
the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on
any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by applicable securities laws.